News

To meet global demand MMUNOPRECISE ANTIBODIES LTD. accelerates the launch of its European B-cell facility expansion at its ModiQuest Research division in Oss, the Netherlands.

MMUNOPRECISE ANTIBODIES LTD. announces that it has closed its previously announced non-brokered private placement financing by issuing a total of 875,000 units of ImmunoPrecise at a price of $0.80 per Unit for gross proceeds of $700,000. READ MORE

May 30, 2018:

IMMUNOPRECISE ANTIBODIES LTD. announces that it has increased its previously announced non-brokered private placement financing (see news releas...

May 29^th, 2018:

IMMUNOPRECISE ANTIBODIES LTD. announces that it proposes to complete a non-brokered private placement financing of 750,000 units (â...

May 24^th, 2018:

IMMUNOPRECISE ANTIBODIES LTD. announces that, as part of its annual review of management and board members, it has appointed Jenni...

May 18^th, 2018:

IMMUNOPRECISE ANTIBODIES LTD. announces the opening of its U.S. Headquarters in Fargo, North Dakota.